Blog
RSS FeedPosted by Michael Wonder on 06 Mar 2019
Patient advocacy groups in Canada with ties to pharma are big boosters for government coverage
5 March 2019 - As the interplay between the pharmaceutical industry and patient advocacy groups undergoes stepped-up scrutiny, a new ...
Posted by Michael Wonder on 05 Mar 2019
Evaluating Canadians’ values for drug coverage decision making
2 March 2019 - Decision makers are facing growing challenges in prioritising drugs for reimbursement because of soaring drug costs and ...
Posted by Michael Wonder on 03 Mar 2019
Biogen responds to CADTH’s updated recommendation regarding coverage for Spinraza
1 March 2019 - CADTH has expanded their recommendations for public reimbursement for SMA patients. ...
Posted by Michael Wonder on 21 Feb 2019
How big pharma donations may influence public drug coverage
21 February 2019 - A new review of 372 patient group submissions to the CADTH – about whether new medicines should ...
Posted by Michael Wonder on 20 Feb 2019
Updates for patients and communities
20 February 2019 - After spending the fall listening to patient groups and exploring how other organisations have involved patients ...
Posted by Michael Wonder on 06 Feb 2019
New opportunity: parallel scientific advice from CADTH and NICE
6 February 2019 - CADTH is pleased to announce a new collaboration with England’s NICE (National Institute for Health and ...
Posted by Michael Wonder on 16 Dec 2018
Proposal to harmonise, streamline and transition the Cancer Drug Implementation Advisory Committee to CADTH
14 December 2018 - Providing customised implementation support to decision-makers at all levels of the health system is a key ...
Posted by Michael Wonder on 13 Nov 2018
Canada's HTA agency releases report on international biosimilar policies
8 November 2018 - The Canadian Agency for Drugs and Technologies in Health (CADTH), the Canadian entity responsible for health ...
Posted by Michael Wonder on 29 Oct 2018
Mavenclad (cladribine tablets) receives positive CADTH Canadian Drug Expert Committee recommendation
29 October 2018 - Funding recommendation marks an important step to provide access to this innovative new oral treatment for Canadians ...
Posted by Michael Wonder on 11 Oct 2018
Ethics in health technology assessment: a systematic review
9 October 2018 - Integration of ethics into health technology assessment remains challenging for HTA practitioners. ...
Posted by Michael Wonder on 10 Sep 2018
Canadian Dermatology Association and Canadian Society of Allergy and Clinical Immunology issue joint statement against the Canadian Agency for Drugs and Technologies in health recommendation
10 September 2018 - Many Canadian eczema sufferers are dealt a difficult blow; many patients face a future with no access ...
Posted by Michael Wonder on 25 Aug 2018
Ensuring patient voices are heard: how patients can contribute to the CADTH Symposium
24 August 2018 - This webinar will outline the process for submitting abstracts and offer tips and ideas to increase the ...
Posted by Michael Wonder on 09 Aug 2018
New from CADTH: Pharmaceutical Reviews Update
9 August 2018 - CADTH is pleased to announce the launch of its new Pharmaceutical Reviews Update newsletter. ...
Posted by Michael Wonder on 09 Aug 2018
David Agnew appointed Chair of the CADTH Board of Directors
8 August 2018 - CADTH is pleased to announce the appointment of Mr. David Agnew to Chair of the CADTH ...
Posted by Michael Wonder on 01 Aug 2018
Canada’s drug agency advised against reimbursing a costly eczema drug — here’s why people are worried
30 July 2018 - Five years ago, Felix Tang’s eczema was a debilitating accompaniment to stress. The chronic inflammatory skin ...